D-0300-2021 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0300-2021 was initiated by Direct Rx on Mar 2, 2021 and is designated Class II. Reason for recall: cGMP deviations: The quantity of active ingredient used for the product lot was inadvertently taken from an ingredient lot from an alternate supplier before that specific lot was formally qualified… The recall status is terminated (terminated Sep 21, 2021). Affected quantity: 17 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 24, 2021
Initiation Date
Mar 2, 2021
Termination Date
Sep 21, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17 bottles

Product description

Nortriptyline HCL capsules, 10 mg, packaged in 30-count bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA, NDC 6191985330

Reason for recall

cGMP deviations: The quantity of active ingredient used for the product lot was inadvertently taken from an ingredient lot from an alternate supplier before that specific lot was formally qualified for use by the manufacturing site.

Distribution pattern

GA

Code information

Lot#: 28DE2002 Exp 10/31/22

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0300-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0300-2021. Report a data issue: hello@regdatalab.com.